“ Innovation, Breakthrough , Quality of Life for Health”
Golden Biotechnology Corporation (GBC, GoldenBiotech) (TPEx: 4132), founded by Mr. Sheng Yung, Liu in 2002, is a leading global biopharmaceutical company. GoldenBiotech focuses on discovery and clinical development of innovative therapeutic new drugs (NCE), and dedicated to improving quality of life by developing products that prevent and treat diseases.
GoldenBiotech discovered from its own screening platforms Antroquinonol® (trade name HOCENA® ), which has been granted more than 150 patents worldwide for its structure, preparation and applications in oncology, cardio-metabolic syndromes, autoimmune diseases, neurodegenerative diseases and infectious diseases. Since 2013, Antroquinonol® was authorized Phase II clinical trial on NSCLC by US FDA and Taiwan FDA and trial completed in 2019. The clinical trials on acute myeloid leukemia (AML) has also completed in 2020, and the multi-national trials on pancreatic cancer and COVID-19 expected to accomplish in mid-2021. Orphan Drug Designations (ODD) were obtained in treatment of pancreatic cancer (US #14-4608 & EU), AML (US#15-4763) and hepatocellular carcinoma (US#15-4881).
GoldenBiotech will be applying for the US Emergency Use Authorization (EUA) once the COVID-19 clinical trial exhibits significant clinical results which can expedite the speed of meeting of urgent market demand in the pandemic. GoldenBiotech has expanded the multi-national clinical centers of trial to the US, Peru and Argentina to accelerate the completion of the Covid-19 trial.
Antroquinonol® exhibits a broad spectrum of activities against malignancies in-vivo and in-vitro, and offers a better solution than the single-action compounds the industry developed so far. Antroquinonol’s multiple, simultaneous, and synergistic actions enable positive outcomes. Antroquinonol® can be used as a monotherapy, combination- or adjuvant-therapy to complement other drugs, or as a best supportive care. Demonstrated safety profile and efficacy make Antroquinonol® an ideal asset in treating diseases and improving overall quality of life of patients.
GoldenBiotech is seeking for out-licensing and/or co-development opportunities to accelerate clinical development and commercialization.